Germany
Japan
United Kingdom
China
Antibodies
LDL Receptor (LDLR) mouse monoclonal antibody, clone C7, Purified
| Applications | FC, IF, WB |
| Reactivities | Bovine, Human |
| Conjugation | Unconjugated |
Mouse monoclonal anti-ATP1A1(NaK ATPase) antibody, clone 464.6, Loading control
| Applications | FC, IHC, WB |
| Reactivities | Canine, Human, Mouse, Porcine, Primate, Rabbit, Rat, Sheep, Xenopus |
| Conjugation | Unconjugated |
Mouse Monoclonal BRG1 Antibody
| Applications | IF, IP, WB |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
USD 600.00
3 Weeks
USD 600.00
3 Weeks
PSMA (FOLH1) mouse monoclonal antibody, clone Y-PSMA2, Purified
| Applications | ELISA, IF, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
Mouse Monoclonal MBP Antibody (2H9)
| Applications | ELISA, FC, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
TA336919 is a replacement of AM06698SU-N.
USD 424.00
2 Weeks
Mouse Monoclonal UCHL1 / PGP9.5 Antibody
| Applications | IF, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
CA50 mouse monoclonal antibody, clone 93, Aff - Purified
| Applications | ELISA, IF |
| Reactivities | Human |
| Conjugation | Unconjugated |
Active filters
Category
- Antibodies
Applications
- IF
Clonalities
- Monoclonal
Conjugates
- Unconjugated
Filter by
Target Symbol
- MAP2K1 (122)
- PDCD1 (88)
- CTAG1B (81)
- MAP2K3 (78)
- KLK8 (63)
- LIPG (63)
- TP53 (63)
- ERCC1 (60)
- ERBB2 (53)
- L1CAM (53)
- MAPK13 (51)
- CDKN2A (49)
- PNMT (48)
- VIM (48)
- EPCAM (47)
- MDM4 (45)
- SYP (42)
- CD163 (41)
- IDO1 (40)
- PECAM1 (40)
- BSG (36)
- LOX (36)
- MLANA (36)
- PTPRE (36)
- APP (35)
- CTNNB1 (35)
- SQSTM1 (35)
- BUB1B (34)
- MYC (34)
- ACAT2 (33)
- CCT8L2 (33)
- CD19 (33)
- MAPK7 (33)
- MIOX (33)
- MOB3B (33)
- MTRF1L (33)
- NME4 (33)
- NPR3 (33)
- PDE4A (33)
- PSMC3 (33)
- SENP2 (33)
- GFAP (32)
- BTK (31)
- CDK2 (31)
- ALDH1L1 (30)
- BTN1A1 (30)
- CD80 (30)
- CHGA (30)
- ERCC4 (30)
- ERG (30)
- FAHD2A (30)
- IGF2BP2 (30)
- KRT7 (30)
- LENG1 (30)
- LIMK1 (30)
- MAPRE2 (30)
- MCL1 (30)
- MMP13 (30)
- PIK3AP1 (30)
- RNF144B (30)
- SMS (30)
- SPG7 (30)
- TACC3 (30)
- TH (30)
- UBE2G2 (30)
- VWA5A (30)
- SNAP25 (29)
- AKT1 (28)
- SNX9 (28)
- ARHGAP25 (27)
- BECN1 (27)
- CCM2 (27)
- CD1C (27)
- ELK3 (27)
- FOXI1 (27)
- GBP2 (27)
- HIBCH (27)
- HOXC11 (27)
- PARVA (27)
- PGAM2 (27)
- PIK3R5 (27)
- SOCS3 (27)
- TAL1 (27)
- AFP (26)
- CD33 (26)
- KRT19 (26)
- ATP5F1B (25)
- POR (25)
- ACAA2 (24)
- ARFGAP1 (24)
- CRYAB (24)
- CYP1A2 (24)
- DTYMK (24)
- DYNC1LI1 (24)
- FGF21 (24)
- IL1A (24)
- LGR5 (24)
- LRATD2 (24)
- MICAL1 (24)
- NHEJ1 (24)
Reactivities
- Human (11503)
- Mouse (7254)
- Rat (6949)
- Monkey (1606)
- Dog (1388)
- Bovine (45)
- Hamster (36)
- Porcine (25)
- Primate (21)
- Rabbit (21)
- Chicken (20)
- Sheep (14)
- Zebrafish (10)
- Canine (9)
- Drosophila (9)
- Mammalian (9)
- Goat (8)
- SARS-CoV (8)
- Xenopus (8)
- Cow (6)
- Feline (6)
- Guinea Pig (6)
- Pig (6)
- Avian (4)
- Equine (4)
- C. elegans (3)
- All Species (2)
- Chimpanzee (2)
- Dengue virus (2)
- Fish (2)
- West Nile Virus (2)
- Yeast (2)
- Yellow Fever Virus (2)
- Beluga (1)
- Carp (1)
- Chlamydomonas (1)
- Drosophila melanogaster (1)
Antibody Hosts
Isotypes
Knockout (KO) Validation
Modifications
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. (32)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (14)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human Fab format, for improved compatibility with existing reagents, assays and techniques. (12)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2a format, for improved compatibility with existing reagents, assays and techniques. (8)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (7)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2b format, for improved compatibility with existing reagents, assays and techniques. (7)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG1 format, for improved compatibility with existing reagents, assays and techniques. (7)
- This reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (6)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (5)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2a format, for improved compatibility with existing reagents, assays and techniques. (5)
- Phospho-specific (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgM format, for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (3)
- This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (3)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original human scFv format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric murine antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Armenian Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgM format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG3 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse scFv antibody fragment format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG2a format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This constant region of this antibody has been modified to bind to Protein A, allowing highly-specific purification of this antibody by Protein A-affinity column. (1)
- This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Mouse scFv format, for improved compatibility with existing reagents, assays and techniques. (1)
- This full-length, reformatted mouse antibody was made using the variable domain sequences of the original Mouse scFv format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse scFv antibody fragment format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted rat antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted rat antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
Assay Types
Families
- Druggable Genome (6467)
- Transmembrane (2002)
- Transcription Factors (1405)
- Protein Kinase (948)
- ES Cell Differentiation/IPS (915)
- Secreted Protein (799)
- Protease (401)
- Stem cell - Pluripotency (401)
- Adult stem cells (175)
- Phosphatase (125)
- P450 (102)
- Embryonic stem cells (99)
- Stem cell relevant signaling - JAK/STAT signaling pathway (76)
- Cancer stem cells (69)
- Stem cell relevant signaling - DSL/Notch pathway (67)
- Ion Channels: Other (65)
- Induced pluripotent stem cells (54)
- Nuclear Hormone Receptor (48)
- Stem cell relevant signaling - TGFb/BMP signaling pathway (34)
- GPCR (29)
- Ion Channels: Potassium (21)
- Stem cell relevant signaling - Wnt Signaling pathway (14)
- Ion Channels: Calcium (1)
- Ion Channels: Cyclic nucleotide gated (1)
- Ion Channels: Sodium (1)
- Ion Channels: Transient receptor potential (1)
Pathways
- Metabolic pathways (1379)
- Pathways in cancer (888)
- MAPK signaling pathway (727)
- Focal adhesion (510)
- Neurotrophin signaling pathway (510)
- Prostate cancer (500)
- Toll-like receptor signaling pathway (483)
- Pancreatic cancer (481)
- Fc epsilon RI signaling pathway (472)
- Progesterone-mediated oocyte maturation (468)
- T cell receptor signaling pathway (468)
- Non-small cell lung cancer (461)
- Chronic myeloid leukemia (450)
- Endometrial cancer (445)
- Melanoma (443)
- Colorectal cancer (434)
- ErbB signaling pathway (434)
- Insulin signaling pathway (426)
- Bladder cancer (419)
- Glioma (412)
- Regulation of actin cytoskeleton (402)
- GnRH signaling pathway (393)
- B cell receptor signaling pathway (364)
- Fc gamma R-mediated phagocytosis (355)
- Cell adhesion molecules (CAMs) (353)
- Acute myeloid leukemia (334)
- Renal cell carcinoma (332)
- Gap junction (330)
- VEGF signaling pathway (323)
- Cell cycle (308)
- Chemokine signaling pathway (307)
- Thyroid cancer (304)
- Natural killer cell mediated cytotoxicity (280)
- Apoptosis (276)
- Leukocyte transendothelial migration (268)
- Oocyte meiosis (252)
- Amyotrophic lateral sclerosis (ALS) (247)
- p53 signaling pathway (246)
- Purine metabolism (244)
- Jak-STAT signaling pathway (225)
- Small cell lung cancer (213)
- Hematopoietic cell lineage (210)
- Melanogenesis (206)
- Alzheimer's disease (202)
- Wnt signaling pathway (202)
- Huntington's disease (200)
- Prion diseases (197)
- Endocytosis (196)
- Vascular smooth muscle contraction (193)
- Long-term depression (187)
- Adherens junction (186)
- Long-term potentiation (183)
- Axon guidance (177)
- Type II diabetes mellitus (167)
- Ubiquitin mediated proteolysis (164)
- Pathogenic Escherichia coli infection (161)
- Parkinson's disease (159)
- Tight junction (159)
- Pyrimidine metabolism (156)
- Dorso-ventral axis formation (152)
- Epithelial cell signaling in Helicobacter pylori infection (146)
- Valine (146)
- Glycolysis / Gluconeogenesis (142)
- mTOR signaling pathway (142)
- leucine and isoleucine degradation (139)
- Adipocytokine signaling pathway (137)
- Primary immunodeficiency (137)
- Cytokine-cytokine receptor interaction (133)
- Nucleotide excision repair (121)
- Basal cell carcinoma (120)
- Tryptophan metabolism (112)
- NOD-like receptor signaling pathway (111)
- Glycerolipid metabolism (109)
- Tyrosine metabolism (108)
- Arginine and proline metabolism (106)
- RIG-I-like receptor signaling pathway (104)
- Systemic lupus erythematosus (103)
- Oxidative phosphorylation (101)
- TGF-beta signaling pathway (101)
- Calcium signaling pathway (97)
- Drug metabolism - cytochrome P450 (87)
- Pyruvate metabolism (86)
- Proteasome (84)
- Arachidonic acid metabolism (80)
- Fatty acid metabolism (79)
- Propanoate metabolism (79)
- beta-Alanine metabolism (79)
- Metabolism of xenobiotics by cytochrome P450 (78)
- Type I diabetes mellitus (76)
- Graft-versus-host disease (75)
- Antigen processing and presentation (72)
- Butanoate metabolism (71)
- Viral myocarditis (71)
- Arrhythmogenic right ventricular cardiomyopathy (ARVC) (68)
- Glutathione metabolism (66)
- Citrate cycle (TCA cycle) (64)
- Fructose and mannose metabolism (64)
- PPAR signaling pathway (64)
- Glycine (63)
- serine and threonine metabolism (63)
- Inositol phosphate metabolism (61)
- Phosphatidylinositol signaling system (59)
- Retinol metabolism (59)
- Maturity onset diabetes of the young (57)
- Cysteine and methionine metabolism (56)
- Lysine degradation (55)
- Linoleic acid metabolism (51)
- Pentose phosphate pathway (51)
- Terpenoid backbone biosynthesis (51)
- Cytosolic DNA-sensing pathway (50)
- Regulation of autophagy (50)
- Amino sugar and nucleotide sugar metabolism (49)
- Base excision repair (48)
- Hypertrophic cardiomyopathy (HCM) (48)
- Neuroactive ligand-receptor interaction (46)
- Allograft rejection (42)
- Autoimmune thyroid disease (42)
- Synthesis and degradation of ketone bodies (42)
- Vibrio cholerae infection (42)
- Dilated cardiomyopathy (40)
- One carbon pool by folate (40)
- Mismatch repair (38)
- Ascorbate and aldarate metabolism (37)
- Cardiac muscle contraction (37)
- Notch signaling pathway (36)
- Lysosome (35)
- Complement and coagulation cascades (34)
- RNA degradation (34)
- Spliceosome (34)
- Caffeine metabolism (33)
- Galactose metabolism (33)
- RNA polymerase (33)
- Hedgehog signaling pathway (32)
- Histidine metabolism (32)
- Non-homologous end-joining (31)
- DNA replication (30)
- Drug metabolism - other enzymes (30)
- SNARE interactions in vesicular transport (30)
- Starch and sucrose metabolism (30)
- Homologous recombination (29)
- Alanine (24)
- Fatty acid elongation in mitochondria (24)
- N-Glycan biosynthesis (24)
- Nicotinate and nicotinamide metabolism (24)
- aspartate and glutamate metabolism (24)
- Folate biosynthesis (22)
- Sphingolipid metabolism (21)
- ECM-receptor interaction (20)
- Porphyrin and chlorophyll metabolism (19)
- Glycosaminoglycan degradation (18)
- Other glycan degradation (18)
- Renin-angiotensin system (18)
- Primary bile acid biosynthesis (16)
- Biosynthesis of unsaturated fatty acids (15)
- Glyoxylate and dicarboxylate metabolism (15)
- Nitrogen metabolism (15)
- Sulfur metabolism (15)
- Circadian rhythm - mammal (12)
- Pantothenate and CoA biosynthesis (12)
- Basal transcription factors (11)
- Methane metabolism (10)
- Androgen and estrogen metabolism (9)
- Asthma (9)
- Glycosphingolipid biosynthesis - ganglio series (9)
- Glycosphingolipid biosynthesis - lacto and neolacto series (9)
- Keratan sulfate biosynthesis (9)
- Selenoamino acid metabolism (9)
- Vitamin B6 metabolism (9)
- Fatty acid biosynthesis (8)
- Phenylalanine metabolism (7)
- leucine and isoleucine biosynthesis (7)
- Glycerophospholipid metabolism (6)
- Olfactory transduction (6)
- Steroid biosynthesis (6)
- Taurine and hypotaurine metabolism (6)
- Aminoacyl-tRNA biosynthesis (4)
- Limonene and pinene degradation (4)
- Pentose and glucuronate interconversions (3)
- ABC transporters (2)